Copyright Reports & Markets. All rights reserved.

Global Selective Cox-2 Inhibitors Market Size, Status and Forecast 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Selective Cox-2 Inhibitors Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 Meloxicam
      • 1.4.3 Celecoxib
      • 1.4.4 Etoricoxib
      • 1.4.5 Imrecoxib
      • 1.4.6 Etodolac
      • 1.4.7 Parecoxib
      • 1.4.8 Other
    • 1.5 Market by Application
      • 1.5.1 Global Selective Cox-2 Inhibitors Market Share by Application (2014-2025)
      • 1.5.2 Rheumatoid Arthritis
      • 1.5.3 Osteoarthritis
      • 1.5.4 Spondylosis Chronica Ankylopoietica
      • 1.5.5 Other
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 Selective Cox-2 Inhibitors Market Size
    • 2.2 Selective Cox-2 Inhibitors Growth Trends by Regions
      • 2.2.1 Selective Cox-2 Inhibitors Market Size by Regions (2014-2025)
      • 2.2.2 Selective Cox-2 Inhibitors Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Challenges
      • 2.3.4 Porter’s Five Forces Analysis

    3 Market Share by Key Players

    • 3.1 Selective Cox-2 Inhibitors Market Size by by Players
      • 3.1.1 Global Selective Cox-2 Inhibitors Revenue by by Players (2014-2019)
      • 3.1.2 Global Selective Cox-2 Inhibitors Revenue Market Share by by Players (2014-2019)
      • 3.1.3 Global Selective Cox-2 Inhibitors Market Concentration Ratio (CR5 and HHI)
    • 3.2 Selective Cox-2 Inhibitors Key Players Head office and Area Served
    • 3.3 Key Players Selective Cox-2 Inhibitors Product/Solution/Service
    • 3.4 Date of Enter into Selective Cox-2 Inhibitors Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global Selective Cox-2 Inhibitors Market Size by Type (2014-2019)
    • 4.2 Global Selective Cox-2 Inhibitors Market Size by Application (2014-2019)

    5 United States

    • 5.1 United States Selective Cox-2 Inhibitors Market Size (2014-2019)
    • 5.2 Selective Cox-2 Inhibitors Key Players in United States
    • 5.3 United States Selective Cox-2 Inhibitors Market Size by Type
    • 5.4 United States Selective Cox-2 Inhibitors Market Size by Application

    6 Europe

    • 6.1 Europe Selective Cox-2 Inhibitors Market Size (2014-2019)
    • 6.2 Selective Cox-2 Inhibitors Key Players in Europe
    • 6.3 Europe Selective Cox-2 Inhibitors Market Size by Type
    • 6.4 Europe Selective Cox-2 Inhibitors Market Size by Application

    7 China

    • 7.1 China Selective Cox-2 Inhibitors Market Size (2014-2019)
    • 7.2 Selective Cox-2 Inhibitors Key Players in China
    • 7.3 China Selective Cox-2 Inhibitors Market Size by Type
    • 7.4 China Selective Cox-2 Inhibitors Market Size by Application

    8 Japan

    • 8.1 Japan Selective Cox-2 Inhibitors Market Size (2014-2019)
    • 8.2 Selective Cox-2 Inhibitors Key Players in Japan
    • 8.3 Japan Selective Cox-2 Inhibitors Market Size by Type
    • 8.4 Japan Selective Cox-2 Inhibitors Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia Selective Cox-2 Inhibitors Market Size (2014-2019)
    • 9.2 Selective Cox-2 Inhibitors Key Players in Southeast Asia
    • 9.3 Southeast Asia Selective Cox-2 Inhibitors Market Size by Type
    • 9.4 Southeast Asia Selective Cox-2 Inhibitors Market Size by Application

    10 India

    • 10.1 India Selective Cox-2 Inhibitors Market Size (2014-2019)
    • 10.2 Selective Cox-2 Inhibitors Key Players in India
    • 10.3 India Selective Cox-2 Inhibitors Market Size by Type
    • 10.4 India Selective Cox-2 Inhibitors Market Size by Application

    11 Central & South America

    • 11.1 Central & South America Selective Cox-2 Inhibitors Market Size (2014-2019)
    • 11.2 Selective Cox-2 Inhibitors Key Players in Central & South America
    • 11.3 Central & South America Selective Cox-2 Inhibitors Market Size by Type
    • 11.4 Central & South America Selective Cox-2 Inhibitors Market Size by Application

    12 International Players Profiles

    • 12.1 Boehringer-Ingelheim
      • 12.1.1 Boehringer-Ingelheim Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 Selective Cox-2 Inhibitors Introduction
      • 12.1.4 Boehringer-Ingelheim Revenue in Selective Cox-2 Inhibitors Business (2014-2019)
      • 12.1.5 Boehringer-Ingelheim Recent Development
    • 12.2 TerSera Therapeutics
      • 12.2.1 TerSera Therapeutics Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 Selective Cox-2 Inhibitors Introduction
      • 12.2.4 TerSera Therapeutics Revenue in Selective Cox-2 Inhibitors Business (2014-2019)
      • 12.2.5 TerSera Therapeutics Recent Development
    • 12.3 Iroko Pharmaceuticals
      • 12.3.1 Iroko Pharmaceuticals Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 Selective Cox-2 Inhibitors Introduction
      • 12.3.4 Iroko Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2014-2019)
      • 12.3.5 Iroko Pharmaceuticals Recent Development
    • 12.4 Apotex
      • 12.4.1 Apotex Company Details
      • 12.4.2 Company Description and Business Overview
      • 12.4.3 Selective Cox-2 Inhibitors Introduction
      • 12.4.4 Apotex Revenue in Selective Cox-2 Inhibitors Business (2014-2019)
      • 12.4.5 Apotex Recent Development
    • 12.5 Yung Shin Pharmaceutical
      • 12.5.1 Yung Shin Pharmaceutical Company Details
      • 12.5.2 Company Description and Business Overview
      • 12.5.3 Selective Cox-2 Inhibitors Introduction
      • 12.5.4 Yung Shin Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2014-2019)
      • 12.5.5 Yung Shin Pharmaceutical Recent Development
    • 12.6 Breckenridge Pharmaceutical
      • 12.6.1 Breckenridge Pharmaceutical Company Details
      • 12.6.2 Company Description and Business Overview
      • 12.6.3 Selective Cox-2 Inhibitors Introduction
      • 12.6.4 Breckenridge Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2014-2019)
      • 12.6.5 Breckenridge Pharmaceutical Recent Development
    • 12.7 Meda Pharmaceuticals
      • 12.7.1 Meda Pharmaceuticals Company Details
      • 12.7.2 Company Description and Business Overview
      • 12.7.3 Selective Cox-2 Inhibitors Introduction
      • 12.7.4 Meda Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2014-2019)
      • 12.7.5 Meda Pharmaceuticals Recent Development
    • 12.8 Cipla
      • 12.8.1 Cipla Company Details
      • 12.8.2 Company Description and Business Overview
      • 12.8.3 Selective Cox-2 Inhibitors Introduction
      • 12.8.4 Cipla Revenue in Selective Cox-2 Inhibitors Business (2014-2019)
      • 12.8.5 Cipla Recent Development
    • 12.9 Glenmark Pharmaceuticals
      • 12.9.1 Glenmark Pharmaceuticals Company Details
      • 12.9.2 Company Description and Business Overview
      • 12.9.3 Selective Cox-2 Inhibitors Introduction
      • 12.9.4 Glenmark Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2014-2019)
      • 12.9.5 Glenmark Pharmaceuticals Recent Development
    • 12.10 Teva
      • 12.10.1 Teva Company Details
      • 12.10.2 Company Description and Business Overview
      • 12.10.3 Selective Cox-2 Inhibitors Introduction
      • 12.10.4 Teva Revenue in Selective Cox-2 Inhibitors Business (2014-2019)
      • 12.10.5 Teva Recent Development
    • 12.11 PuraCap Pharmaceutical
    • 12.12 Almirall Limited
    • 12.13 Lupin Pharmaceuticals
    • 12.14 Aurobindo Pharma
    • 12.15 Pfizer
    • 12.16 Mylan
    • 12.17 Shire Pharmaceuticals
    • 12.18 Bayer
    • 12.19 Novacap
    • 12.20 Abbott
    • 12.21 Geri-Care
    • 12.22 Perrigo
    • 12.23 Kopran
    • 12.24 Merck
    • 12.25 Hengrui pharmaceutical
    • 12.26 Kelun Group
    • 12.27 Qilu Pharmaceutical
    • 12.28 Taro Pharmaceuticals

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Regions
    • 13.2 United States
    • 13.3 Europe
    • 13.4 China
    • 13.5 Japan
    • 13.6 Southeast Asia
    • 13.7 India
    • 13.8 Central & South America
    • 13.9 Market Size Forecast by Product (2019-2025)
    • 13.10 Market Size Forecast by Application (2019-2025)

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 12.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      In 2018, the global Selective Cox-2 Inhibitors market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

      This report focuses on the global Selective Cox-2 Inhibitors status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Selective Cox-2 Inhibitors development in United States, Europe and China.

      The key players covered in this study
      Boehringer-Ingelheim
      TerSera Therapeutics
      Iroko Pharmaceuticals
      Apotex
      Yung Shin Pharmaceutical
      Breckenridge Pharmaceutical
      Meda Pharmaceuticals
      Cipla
      Glenmark Pharmaceuticals
      Teva
      PuraCap Pharmaceutical
      Almirall Limited
      Lupin Pharmaceuticals
      Aurobindo Pharma
      Pfizer
      Mylan
      Shire Pharmaceuticals
      Bayer
      Novacap
      Abbott
      Geri-Care
      Perrigo
      Kopran
      Merck
      Hengrui pharmaceutical
      Kelun Group
      Qilu Pharmaceutical
      Taro Pharmaceuticals 

      Market segment by Type, the product can be split into
      Meloxicam
      Celecoxib
      Etoricoxib
      Imrecoxib
      Etodolac
      Parecoxib
      Other

      Market segment by Application, split into
      Rheumatoid Arthritis
      Osteoarthritis
      Spondylosis Chronica Ankylopoietica
      Other

      Market segment by Regions/Countries, this report covers
      United States
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global Selective Cox-2 Inhibitors status, future forecast, growth opportunity, key market and key players.
      To present the Selective Cox-2 Inhibitors development in United States, Europe and China.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by product type, market and key regions.

      In this study, the years considered to estimate the market size of Selective Cox-2 Inhibitors are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025
      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now